BioPharma Credit Past Earnings Performance
Past criteria checks 3/6
BioPharma Credit has been growing earnings at an average annual rate of 7.2%, while the Capital Markets industry saw earnings growing at 18.2% annually. Revenues have been declining at an average rate of 6.1% per year. BioPharma Credit's return on equity is 6.2%, and it has net margins of 81.8%.
Key information
7.2%
Earnings growth rate
-0.9%
EPS growth rate
| Capital Markets Industry Growth | 15.2% |
| Revenue growth rate | -6.1% |
| Return on equity | 6.2% |
| Net Margin | 81.8% |
| Next Earnings Update | 14 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How BioPharma Credit makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 21 | 104 | 85 | 19 | 0 |
| 30 Sep 21 | 109 | 89 | 20 | 0 |
| 30 Jun 21 | 114 | 93 | 21 | 0 |
| 31 Mar 21 | 112 | 91 | 21 | 0 |
| 31 Dec 20 | 110 | 89 | 21 | 0 |
| 30 Sep 20 | 111 | 86 | 25 | 0 |
| 30 Jun 20 | 112 | 83 | 30 | 0 |
| 31 Mar 20 | 132 | 103 | 29 | 0 |
| 31 Dec 19 | 151 | 122 | 29 | 0 |
| 30 Sep 19 | 146 | 119 | 26 | 0 |
| 30 Jun 19 | 142 | 115 | 24 | 0 |
| 31 Mar 19 | 120 | 93 | 23 | 0 |
| 31 Dec 18 | 97 | 70 | 23 | 0 |
| 31 Dec 17 | 34 | 27 | 7 | 0 |
Quality Earnings: B3P has high quality earnings.
Growing Profit Margin: B3P's current net profit margins (81.8%) are higher than last year (81%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: B3P's earnings have grown by 7.2% per year over the past 5 years.
Accelerating Growth: B3P's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: B3P had negative earnings growth (-4.7%) over the past year, making it difficult to compare to the Capital Markets industry average (-14.7%).
Return on Equity
High ROE: B3P's Return on Equity (6.2%) is considered low.